Table 2.
Adverse reactions to immunotherapy
| Recording |
|---|
| Local reactions |
| Grade 1 (L1): local swelling or nodules <12 cm in diameter |
| Grade 2 (L2): local reaction ≥12 cm in diameter |
| Systemic reactions |
| Grade 1 (S1): exacerbation of patient-specific symptoms (mild allergy: itchy eyes, sneezing, cough, atopic eczema) |
| Grade 2 (S2): moderate allergic reaction (wheezing, breathlessness, angioedema, generalized urticaria) |
| Grade 3 (S3): anaphylactic shock |
| Allergen | Children | Adolescents | ||||||
|---|---|---|---|---|---|---|---|---|
| L1 | L2 | S1 | S2 | L1 | L2 | S1 | S2 | |
| Grass pollen | (488) 228 | 28 | 22 | 4 | (374) 104 | 19 | 5 | 0 |
| Tree pollen | (489) 196 | 17 | 12 | 1 | (340) 75 | 18 | 2 | 0 |
| Tree/grass | (174) 89 | 11 | 0 | 0 | (127) 26 | 5 | 0 | 0 |
| Mites | (470) 153 | 12 | 7 | 1 | (332) 114 | 20 | 0 | 8 |
| Mixed | (56) 48 | 11 | 4 | 1 | (61) 31 | 7 | 0 | 0 |
Numbers of recorded local or systemic reactions for each allergen extract (total number of patients treated with each extract shown in brackets). There were no recorded cases of anaphylactic shock.
Dose reduction occurred 153 times in children and 67 times in adolescents following LR<10 cm, 31 times in children and 10 times in adolescents following large local reactions, eight times in children following mild systemic symptoms and two times in children following moderate systemic symptoms.